At a glance
ClinicalIndex Comparison RecordN/ACompleted· 60 enrolled
Drug / intervention
Entecavirdrug
Likely dose
Entecavir 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HBV Viral Suppression by Entecavir in Adefovir Partial Responders
In Brief
An observational study evaluating Entecavir for Hepatitis B. Completed, enrolled 60 participants across 6 sites.
Detailed Summary
We propose a largely retrospective study with short-term prospective follow-up in a subgroup of patients who have not yet been treated with 48 weeks of entecavir following partial response to adefovir. The aim of the study is to describe sequential virologic response to adefovir and entecavir.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedJun 2008
Primary CompletionOct 2011
TodayJul 2026
First PostedJun 24, 2008
Enrollment StartMay 1, 2008
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 18.0 years ago
Interventions
Entecavirdrug
0.5 or 1 mg dose qd